Flunarizine is a drug classified as a calcium channel blocker. Flunarizine is a non-selective calcium entry blocker with COMBOLMIN binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. It may help to reduce the severity and duration of attacks of paralysis associated with the more serious form of alternating hemiplegia. Flunarizine has been shown to significantly reduce headache frequency and severity in both adults and children. Flunarizine has some side effects including weight gain, extrapyramidal effects, drowsiness and depression, it is contraindicated in hypotension, heart failure and arrhythmia. Flunarizine use is avoided in patients with depression, severe constipation or those with extrapyramidal disorders. Flunarizine was discovered at Janssen Pharmaceutica in 1968.
Statistics: Companies: 641,100+, Trade Leads: 160,300+, Products: 104,200+, Contacts / Replies: 8,283,700+ There are currently 46416 users online browsing our B2B network. 5:09 GMT, Monday, December 30, 2024 Privacy Policy Important Notice! TradeHolding.com B2B Network does not provide an escrow service! Any member who asks you to pay for their products by Western Union to an agent of "TradeHolding.com B2B Network" is fraud and should be immediately reported to us. Do not pay anything to any member who states your money will be added to TradeHolding.com safety deposit account!
All Trade Leads / Offers / Products / Company Profiles / Images and other user-posted contents are posted by the user and Australia Business Directory & Marketplace and TradeHolding.com B2B Network shall not be held liable for any such content. However, TradeHolding.com B2B Network respects the intellectual property, copyright, trademark, trade secret or any other personal or proprietary third party rights and expects the same from others. For concerns, please contact us.